What the US CRO market can teach Brazil before the wave arrives.
In the United States, when someone says "CRO," the immediate question should be: "Which CRO, for whom, doing what?" Because there isn't a single CRO market there. There are multiples, and each one operates on a different logic.
There are big pharma CROs, for example, IQVIA, ICON, Parexel, Syneos Health, running global Phase III trials with thousands of patients, budgets of tens to hundreds of millions of dollars, and the infrastructure to operate in 20+ countries simultaneously. There are niche therapeutic CROs, specializing in oncology, rare diseases, gastrointestinal issues, or metabolism, which charge several times more because they have in-depth knowledge of a particular protocol and can deliver at a speed that generalists cannot commit to due to their processes. There are CROs that don't run the entire trial, only delivering a portion such as regulatory, biostatistical, and pharmacovigilance as a pluggable service. And there are small regional CROs, which thrive on early-stage biotechs and Phase I trials, with a lower average ticket price per study and an almost artisanal relationship with the client.
The point isn't the size of these companies. It's that each one sells something different, to a different buyer, with a different pricing logic. No one should compare a CRO with annual revenue of ~$10-15B to a boutique oncology CRO using the same yardstick. Nor do the clients of these CROs do that. It would be like comparing a tertiary hospital to a specialized clinic; they serve different purposes.
Brazil is about to experience this — it just doesn't know it yet.
With the new clinical research law (Law 14.874/2024), Brazil is entering a phase that the US and even some other places in the world have already experienced some time ago: more players entering the market, more capital available, more international sponsors, especially Chinese ones, eyeing LatAm as an alternative route to the US, looking here as a viable option for clinical trials made in Brazil.
The numbers speak for themselves: Brazil is already responsible for approximately 3% of global clinical trials (vs. approximately 30% in the US), but this percentage has recently grown. See the Interfarma study on the subject. Chinese sponsors, who represented less than 5% of new studies in Brazil in 2019, will account for approximately 15-20% in 2024. This is good news. More study volume, more investment in research infrastructure, more opportunities for those who are already structured.
But it also means that, in the next 3-5 years, we're going to see a wave of new entrants, small CROs, spin-offs, consultancies that will become CROs, research sites that will try to become CROs, all competing for the same funnel of sponsors who don't yet know the local ecosystem very well.
And here's the real risk: in Brazil today, the natural tendency of an immature market is to compete on price. It's the easiest way to explain this to a foreign sponsor who lacks the background to assess technical differentiation, regulatory quality history, or execution capacity. Price is the easiest metric to compare on a spreadsheet, and that's why it's the first weapon every new entrant pulls out.
Why competing on price is the trap.
In the US, the CROs that survived and grew didn't succeed by charging less. They succeeded by knowing exactly which market segment they would serve, whether it was a therapeutic, functional, geographic area, or the client's developmental stage, and charging what that specialization is worth.
The evidence is in the numbers: CROs specializing in therapeutic niches (oncology, rare diseases) operate in a very healthy way and do not necessarily charge less for it.
This is doubly important for those considering Brazil as a Latin American CRO hub: international sponsors, especially those who have already worked with American or European CROs, are not buying a commodity. They are buying regulatory predictability, patient recruitment capacity, a clean audit history, and a team that understands the protocol as well as they do. A low price without these fundamentals might attract a serious sponsor, but they will soon realize they made a mistake. A low price attracts sponsors who are testing the market with the lowest possible risk, and who will leave as soon as they encounter a problem, because they never had a relationship of trust to begin with.
Furthermore, the mathematics of execution is unforgiving: when you compete on price, you compete on margin, and when you compete on margin, the first things that get squeezed are operational quality, monitoring, data management, and deadlines. And that's precisely what the new Brazilian market cannot afford to compromise, because Brazil's reputation as a destination for clinical research is still being built.
A poorly executed trial today can cost a country's reputation tomorrow, and that reputation takes years to recover.
What should the developers of this new market do differently?
If you are a founder, investor, or executive thinking about entering or growing in the Brazilian CRO sector now, the question that matters more than "how much will I charge" is: in which segment of this heterogeneous market do I want to be a leader?
Here are some concrete routes, looking at what has already worked elsewhere:
Specialization in therapy, mastering oncology, rare diseases, or a specific therapeutic area instead of trying to be a generalist from day one. Example: some oncology-focused CROs in the US grow 15-20% annually, vs. 5-8% for generalists.
Functional specialization: excelling in one part of the chain (regulatory, biologics, patient recruitment) and selling that as a pluggable service to sponsors and even other CROs.
Specialization during internships should focus on Phase I/II biotech companies, where trust is more important than price, instead of directly competing with those already at Phase III scale.
A regulatory and cultural bridge for sponsors from China and other regions, being the CRO that translates not only the language but also the Brazilian and Latin American regulatory process in a way that reduces the anxiety of those who have never operated here. This differentiator is worth a premium price.
None of these routes compete on price as the main argument. They all compete on specialization, predictability, and trust, which are precisely the assets that a developing market, like the Brazilian one now, most needs to build before the wave of new entrants arrives and tries to solve everything by offering discounts.
A true reputation cannot be bought.
Comments